ShopSpell

Acute Myelogenous Leukemia Genetics, Biology and Therapy [Hardcover]

$48.99     $54.99    11% Off      (Free Shipping)
100 available
  • Category: Books (Medical)
  • ISBN-10:  0387692576
  • ISBN-10:  0387692576
  • ISBN-13:  9780387692579
  • ISBN-13:  9780387692579
  • Publisher:  Springer
  • Publisher:  Springer
  • Pages:  280
  • Pages:  280
  • Binding:  Hardcover
  • Binding:  Hardcover
  • Pub Date:  01-Feb-2009
  • Pub Date:  01-Feb-2009
  • SKU:  0387692576-11-SPRI
  • SKU:  0387692576-11-SPRI
  • Item ID: 100447753
  • List Price: $54.99
  • Seller: ShopSpell
  • Ships in: 5 business days
  • Transit time: Up to 5 business days
  • Delivery by: Jul 15 to Jul 17
  • Notes: Brand New Book. Order Now.

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

Acute myelogenous leukemia (AML) is the most common form of leukemia in adults and is a deadly form of malignancy. This book details the work of pioneers in genetic mechanisms, targeted therapy, biology and mouse models for acute myelogenous leukemia.

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

The Leukemia Stem Cell.- Epigenetic Mechanisms in AML  A Target for Therapy.- Chromosomal Translocations in AML: Detection and Prognostic Significance.- Chromosomal Deletions in AML.- Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloidls:
Add Review